Jade Biosciences Quarterly Cash Flow Statement
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
14.39+0.24 (+1.70%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jade Biosciences free cash flow
In the quarter ended Jun 30, 2026, Jade Biosciences generated -$43.7 million of operating cash flow. That left free cash flow of -$43.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Jade Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -55.77M | -40.37M | -31.93M | -25.18M | -32.13M | -38.17M | -5.43M | -16.28M | -24.77M | -23.19M | -20.41M | -19.56M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 9.00K | 9.00K | 9.00K | 12.00K | 1.00K | 4.00K | 8.00K | 218.00K | 28.00K | 28.00K | 28.00K | 25.00K |
| Stock-Based Compensation | 13.61M | 7.41M | 9.40M | 4.29M | 3.90M | 2.42M | 1.24M | 2.00M | 3.87M | 4.20M | 3.25M | 3.24M |
| Change in Working Capital | -732.00K | 7.77M | -9.90M | -5.29M | 1.41M | 2.37M | -472.00K | 302.00K | -1.98M | -885.00K | -703.00K | -1.93M |
| Operating Cash Flow | -43.66M | -24.08M | -33.65M | -22.12M | -20.16M | -18.76M | -11.05M | -6.80M | -20.43M | -23.67M | -14.80M | -15.61M |
| Capital Expenditures | — | — | -3.00K | -57.00K | — | — | — | — | — | — | -64.00K | -32.00K |
| Investing Cash Flow | -97.63M | -8.47M | -98.16M | -148.71M | -12.99M | 12.85M | 13.13M | 0 | 18.00M | 8.83M | 5.65M | -13.13M |
| Financing Cash Flow | 193.52M | -795.00K | 170.16M | 0 | 191.31M | -700.00K | 554.00K | 94.77M | 24.38M | 471.00K | 463.00K | 20.00K |
| Net Change in Cash | 52.16M | -33.35M | 38.33M | -170.84M | 171.01M | -19.46M | 2.64M | 87.97M | 21.95M | -14.37M | -8.69M | -28.72M |
| Free Cash Flow | -43.66M | -24.08M | -33.65M | -22.18M | -20.16M | -18.76M | -11.05M | -6.80M | -20.43M | -23.67M | -14.86M | -15.64M |
This table shows 12 quarterly periods of Jade Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JBIO's reporting calendar. What is a cash flow statement?